Using government data to understand the use and availability of medicines for hypertension and diabetes: lessons from Peru
Open Access
- 18 November 2022
- journal article
- research article
- Published by Springer Science and Business Media LLC in Journal of Pharmaceutical Policy and Practice
- Vol. 15 (1), 1-9
- https://doi.org/10.1186/s40545-022-00481-5
Abstract
Regular measurement of the availability and use of key medicines for non-communicable diseases allows the tracking of progress to achieve equitable access to medicines. Using a country-level public sector monitoring system for medicine supply, we aim to evaluate the availability and use of losartan 50 mg tablets and metformin 850 mg tablets between 2015 and 2020 investigating the impact of different policy changes and the COVID-19 pandemic. Data from the Peruvian National System of Medicine Supply were analyzed using an interrupted time series analysis with known and unknown structural breaks. The outcomes assessed were medicine use (monthly doses dispensed at facilities over time) and medicine availability (proportion of facilities that reported having the medicine available). The use of losartan and metformin at the primary level of care had a linear increasing trend over the period of analysis. In secondary and tertiary levels of care, there were no increases but some significant level and trend changes of doses dispensed at different times between 2017 to 2019, but none were related to the change of procurement procedures. At all levels of care, the COVID-19 onset in April 2020 caused an abrupt drop in doses dispensed especially at the primary level. Regarding availability, we found an increasing linear trend in the primary level of care for both medicines. In secondary and tertiary levels of care, the availability fluctuated between 40 and 95%. The onset of the COVID-19 pandemic did not significantly impact medicine availability, except for losartan in the tertiary level of care. The availability and proper dispensing of first-line medicines for hypertension and diabetes is an essential factor for sustainable and equitable treatment. Health care systems need to be prepared for forecasting the increasing demand of medicines for chronic diseases, but also to maintain effective medicine supply chains during humanitarian crisis like pandemics.Keywords
Funding Information
- Leona M. and Harry B. Helmsley Charitable Trust (ACCISS project)
This publication has 28 references indexed in Scilit:
- Interrupted time series analysis in drug utilization research is increasing: systematic review and recommendationsJournal of Clinical Epidemiology, 2015
- Medicines availability for non-communicable diseases: the case for standardized monitoringGlobalization and Health, 2015
- Utilization of oral antidiabetic medications in Taiwan following strategies to promote access to medicines for chronic diseases in community pharmaciesJournal of Pharmaceutical Policy and Practice, 2015
- Evidence on access to medicines for chronic diseases from household surveys in five low- and middle-income countriesHealth Policy and Planning, 2014
- Use of Interrupted Time Series Analysis in Evaluating Health Care Quality ImprovementsAcademic Pediatrics, 2013
- Access to medicines in Latin America and the Caribbean (LAC): a scoping studyBMJ Open, 2013
- Improving responsiveness of health systems to non-communicable diseasesThe Lancet, 2013
- Access to medicines from a health system perspectiveHealth Policy and Planning, 2012
- Availability, price and affordability of cardiovascular medicines: A comparison across 36 countries using WHO/HAI dataBMC Cardiovascular Disorders, 2010
- Segmented regression analysis of interrupted time series studies in medication use researchJournal of Clinical Pharmacy & Therapeutics, 2002